Text Size
1 study found for:    NCT00109161

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
To Top

† Indicates status has not been verified in more than two years